Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOFRONTERA INC.

(BFRI)
  Report
Delayed Nasdaq  -  03:59:50 2023-01-27 pm EST
0.9182 USD   -0.69%
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
01/09Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
CI
01/09Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M

11/14/2022 | 08:47am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOFRONTERA AG -2.90% 1.34 Delayed Quote.-12.13%
BIOFRONTERA INC. -0.69% 0.9182 Delayed Quote.0.17%
All news about BIOFRONTERA INC.
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
01/09Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evalua..
CI
01/09Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended D..
CI
2022Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
AQ
2022Biofrontera Inc. : Change in Directors or Principal Officers, Submission of Matters to a V..
AQ
2022Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investo..
GL
2022Biofrontera inc. to participate in renmark's virtual non-deal roadshow series on wednes..
GL
2022Biofrontera inc. to participate in renmark's virtual non-deal roadshow series on wednes..
AQ
2022Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz«-PDT for the Treatment o..
GL
2022Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Trea..
CI
More news
Analyst Recommendations on BIOFRONTERA INC.
More recommendations
Financials (USD)
Sales 2022 28,8 M - -
Net income 2022 0,27 M - -
Net Debt 2022 - - -
P/E ratio 2022 61,2x
Yield 2022 -
Capitalization 24,5 M 24,5 M -
Capi. / Sales 2022 0,85x
Capi. / Sales 2023 0,55x
Nbr of Employees 69
Free-Float 57,6%
Chart BIOFRONTERA INC.
Duration : Period :
Biofrontera Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,92 $
Average target price 15,50 $
Spread / Average Target 1 588%
EPS Revisions
Managers and Directors
Erica L. Monaco Chief Executive, Operating & Financial Officer
Fred Leffler Chief Financial Officer
Hermann LŘbbert Executive Chairman
Armin Ollig Vice President-Information Technology
Daniel Hakansson General Counsel & Head-Compliance
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA INC.0.17%25
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-6.49%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
MERCK & CO., INC.-5.02%267 180